Clinical Trial Detail

NCT ID NCT03865082
Title Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Idera Pharmaceuticals, Inc.
Indications

colorectal cancer

laryngeal squamous cell carcinoma

oropharynx cancer

hypopharynx cancer

oral squamous cell carcinoma

Therapies

IMO-2125 + Ipilimumab + Nivolumab

Age Groups: senior adult

Additional content available in CKB BOOST